164 related articles for article (PubMed ID: 36794276)
1. Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis.
Xun X; Ai J; Feng F; Hong P; Rai S; Liu R; Zhang B; Zhou Y; Hu H
Front Pharmacol; 2023; 14():1108772. PubMed ID: 36794276
[No Abstract] [Full Text] [Related]
2. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.
Huang Q; Mei Z; Han X
Front Oncol; 2022; 12():972767. PubMed ID: 36119468
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
[No Abstract] [Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK
BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
10. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis.
Hu Y; Chen P; Xiang F
J Oncol; 2023; 2023():8740221. PubMed ID: 36816360
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
Taher NO; Ghaddaf AA; Al-Ghamdi SA; Homsi JJ; Al-Harbi BJ; Alomari LK; Almarzouki HS
Front Med (Lausanne); 2022; 9():884608. PubMed ID: 35615084
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Li Z; Guo F; Han Y; Wang J; Xu B
Oncol Res Treat; 2022; 45(10):608-617. PubMed ID: 35882206
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Zhou Y; He M; Li R; Peng Y; Li F; Li S; Yang M
Biomed Res Int; 2021; 2021():5537899. PubMed ID: 34532503
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.
Shin S; Noh Y
Ther Clin Risk Manag; 2018; 14():833-847. PubMed ID: 29765225
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Ouyang D; Ma YZ; Zou J; Wang YL; Chen Z; Yang YY; Zou B; Li X; Cao JZ
Front Pharmacol; 2022; 13():911810. PubMed ID: 35991879
[No Abstract] [Full Text] [Related]
18. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis.
Xie R; Huang H; Chen T; Huang X; Chen C
Front Pharmacol; 2023; 14():1228225. PubMed ID: 37829303
[No Abstract] [Full Text] [Related]
20. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Totzeck M; Mincu RI; Rassaf T
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
